We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vaso Gains More Than 65% in Three Months: What's Driving the Stock?
Read MoreHide Full Article
Vaso Corporation’s (VASO - Free Report) investors have been experiencing some short-term gains from the stock lately. Shares of the Plainview, NY-based diversified healthcare-focused company gained 65.1% in the past three months compared with the industry’s 7.1% rise. It has also outperformed the sector and the S&P 500’s gains of 8.3% and 3.5%, respectively, in the same time frame.
Two major developments of VASO in recent months include the announcement of its promising second-quarter 2026 results and the completion of the sale of NetWolves Network Services LLC (NetWolves) to COEO Solutions, LLC (both in August).
In the second quarter, the company reported higher revenues and improved profitability, mainly driven by growth in professional sales services and equipment. Vaso’s continuing operations are focused on professional sales services and proprietary medical equipment and software following the divestiture of its healthcare IT business. Professional sales services benefited from higher diagnostic imaging equipment deliveries, while equipment revenues increased on stronger deliveries in China.
Management highlighted the improvement in operating efficiency and profitability following the divestiture of the healthcare IT business. VASO also completed the sale of its NetWolves network services business in July 2026, completing its exit from network and IT services. The company intends to focus its resources on the continued development of its healthcare businesses, including its professional sales services operations and proprietary medical products.
VASO’s Three-Month Price Comparison
Image Source: Zacks Investment Research
Over the past three months, the stock’s performance has remained strong, outperforming its peers like QT Imaging Holdings, Inc. (QTI - Free Report) and Aspira Women’s Health Inc. (AWHL - Free Report) . QT Imaging and Aspira’s shares have lost 29.6% and 30.2%, respectively, in the same time frame.
Despite broader risks from its reliance on GE Healthcare Technologies, Inc. (GEHC - Free Report) and competitive and regulatory pressures across healthcare markets, the favorable share price movement suggests VASO is well-positioned to sustain its positive momentum at present.
Vaso is a healthcare-focused company centered on professional sales services and proprietary medical products. Through VasoHealthcare, it represents GE HealthCare diagnostic imaging and ultrasound equipment, while VasoMedical designs, manufactures and markets cardiovascular monitoring, diagnostic and therapeutic devices, along with related cloud-based software. Following its recent divestitures, Vaso has exited the network and IT services business.
VASO's Healthcare Growth and Revenue Visibility
VasoHealthcare’s exclusive representation agreement with GE HealthCare provides continuity for the company’s largest operating business and extends the relationship through the end of the decade. Recent performance also indicates healthy activity in the channel, with higher diagnostic imaging deliveries supporting professional sales services revenue, gross profit and operating income. Continued penetration of the GEHC product portfolio therefore remains an important driver of Vaso’s operating momentum.
VASO continues to book new business ahead of equipment deliveries, resulting in higher deferred commission revenue. The company also has a meaningful level of unsatisfied performance obligations under executed contracts. Commission revenue is recognized when the underlying equipment is delivered and accepted, making the accumulated order activity a source of visibility into potential future revenue and a more predictable pipeline for VasoHealthcare.
VasoMedical broadens the company’s healthcare exposure beyond the GE HealthCare relationship through cardiovascular monitoring devices, therapeutic systems and the ARCS cloud-based SaaS platform. Its products are sold across domestic and international markets, while recent equipment growth was supported by stronger deliveries in China. This gives Vaso an independent platform for product and geographic expansion.
Vaso’s Portfolio Focus and Financial Flexibility
The sales of VasoHealthcare IT and NetWolves completed Vaso’s exit from network and IT services. The streamlined portfolio allows management to direct resources toward VasoHealthcare and VasoMedical, simplifying the business model and concentrating attention on healthcare operations where the company intends to pursue its growth strategy.
Vaso continues to generate positive operating cash flow and maintains substantial cash resources. This financial position gives the company flexibility to fund its existing operations, support product and service expansion, improve the equipment business and evaluate partnership opportunities without making those initiatives dependent on external financing.
Challenges Ahead of VASO
VASO faces two key challenges. First, its professional sales services business remains heavily dependent on its longstanding relationship with GEHC, making results sensitive to product availability, delivery timing and the continuation of the sales representation agreement. Second, the proprietary equipment business operates in competitive and regulated medical-device markets, where product acceptance, regulatory requirements and margin pressure can constrain growth. These risks could limit operating consistency even as Vaso sharpens its healthcare focus.
Vaso Stock’s Valuation
VASO's trailing 12-month P/S of 0.6X is lower than the industry’s average of 4.6X but is higher than its two-year median of 0.3X.
Image Source: Zacks Investment Research
QT Imaging and Aspira’s trailing 12-month P/S currently stand at 1.5X and 1.6X, respectively, in the same time frame.
Our Final Take on VASO
Vaso’s strong share-price momentum appears to have a fundamental foundation, supported by its increasingly healthcare-focused business model, healthy operating momentum and a more streamlined portfolio. Together, its established sales platform and proprietary medical-products business provide multiple avenues for continued growth.
However, sustaining the rally will require consistent execution. Dependence on GE HealthCare and the competitive and regulated nature of the medical-device market remain key considerations and could moderate the pace of improvement if pressures intensify.
From a valuation standpoint, VASO still appears reasonably positioned despite its strong recent appreciation, as the stock continues to trade below the broader industry valuation. This suggests that successful execution of its healthcare-focused strategy could support further upside. However, the stock is now valued above its own recent historical average, indicating that investors have already begun pricing in some of the improvement in its business prospects. Consequently, additional appreciation will increasingly depend on sustained operating progress and successful conversion of its order pipeline into recognized business.
For existing shareholders, Vaso’s clearer healthcare focus, established operating platform and financial flexibility support staying invested. Prospective investors may also find VASO worth considering, although the magnitude of the recent rally warrants some caution. The momentum has scope to continue, but maintaining it will require the company to translate its strategic repositioning and growth opportunities into consistent operational and financial improvement.
View the Zacks #1 Rank List
Image: Bigstock
Vaso Gains More Than 65% in Three Months: What's Driving the Stock?
Vaso Corporation’s (VASO - Free Report) investors have been experiencing some short-term gains from the stock lately. Shares of the Plainview, NY-based diversified healthcare-focused company gained 65.1% in the past three months compared with the industry’s 7.1% rise. It has also outperformed the sector and the S&P 500’s gains of 8.3% and 3.5%, respectively, in the same time frame.
Two major developments of VASO in recent months include the announcement of its promising second-quarter 2026 results and the completion of the sale of NetWolves Network Services LLC (NetWolves) to COEO Solutions, LLC (both in August).
In the second quarter, the company reported higher revenues and improved profitability, mainly driven by growth in professional sales services and equipment. Vaso’s continuing operations are focused on professional sales services and proprietary medical equipment and software following the divestiture of its healthcare IT business. Professional sales services benefited from higher diagnostic imaging equipment deliveries, while equipment revenues increased on stronger deliveries in China.
Management highlighted the improvement in operating efficiency and profitability following the divestiture of the healthcare IT business. VASO also completed the sale of its NetWolves network services business in July 2026, completing its exit from network and IT services. The company intends to focus its resources on the continued development of its healthcare businesses, including its professional sales services operations and proprietary medical products.
VASO’s Three-Month Price Comparison
Image Source: Zacks Investment Research
Over the past three months, the stock’s performance has remained strong, outperforming its peers like QT Imaging Holdings, Inc. (QTI - Free Report) and Aspira Women’s Health Inc. (AWHL - Free Report) . QT Imaging and Aspira’s shares have lost 29.6% and 30.2%, respectively, in the same time frame.
Despite broader risks from its reliance on GE Healthcare Technologies, Inc. (GEHC - Free Report) and competitive and regulatory pressures across healthcare markets, the favorable share price movement suggests VASO is well-positioned to sustain its positive momentum at present.
Vaso is a healthcare-focused company centered on professional sales services and proprietary medical products. Through VasoHealthcare, it represents GE HealthCare diagnostic imaging and ultrasound equipment, while VasoMedical designs, manufactures and markets cardiovascular monitoring, diagnostic and therapeutic devices, along with related cloud-based software. Following its recent divestitures, Vaso has exited the network and IT services business.
VASO's Healthcare Growth and Revenue Visibility
VasoHealthcare’s exclusive representation agreement with GE HealthCare provides continuity for the company’s largest operating business and extends the relationship through the end of the decade. Recent performance also indicates healthy activity in the channel, with higher diagnostic imaging deliveries supporting professional sales services revenue, gross profit and operating income. Continued penetration of the GEHC product portfolio therefore remains an important driver of Vaso’s operating momentum.
VASO continues to book new business ahead of equipment deliveries, resulting in higher deferred commission revenue. The company also has a meaningful level of unsatisfied performance obligations under executed contracts. Commission revenue is recognized when the underlying equipment is delivered and accepted, making the accumulated order activity a source of visibility into potential future revenue and a more predictable pipeline for VasoHealthcare.
VasoMedical broadens the company’s healthcare exposure beyond the GE HealthCare relationship through cardiovascular monitoring devices, therapeutic systems and the ARCS cloud-based SaaS platform. Its products are sold across domestic and international markets, while recent equipment growth was supported by stronger deliveries in China. This gives Vaso an independent platform for product and geographic expansion.
Vaso’s Portfolio Focus and Financial Flexibility
The sales of VasoHealthcare IT and NetWolves completed Vaso’s exit from network and IT services. The streamlined portfolio allows management to direct resources toward VasoHealthcare and VasoMedical, simplifying the business model and concentrating attention on healthcare operations where the company intends to pursue its growth strategy.
Vaso continues to generate positive operating cash flow and maintains substantial cash resources. This financial position gives the company flexibility to fund its existing operations, support product and service expansion, improve the equipment business and evaluate partnership opportunities without making those initiatives dependent on external financing.
Challenges Ahead of VASO
VASO faces two key challenges. First, its professional sales services business remains heavily dependent on its longstanding relationship with GEHC, making results sensitive to product availability, delivery timing and the continuation of the sales representation agreement. Second, the proprietary equipment business operates in competitive and regulated medical-device markets, where product acceptance, regulatory requirements and margin pressure can constrain growth. These risks could limit operating consistency even as Vaso sharpens its healthcare focus.
Vaso Stock’s Valuation
VASO's trailing 12-month P/S of 0.6X is lower than the industry’s average of 4.6X but is higher than its two-year median of 0.3X.
Image Source: Zacks Investment Research
QT Imaging and Aspira’s trailing 12-month P/S currently stand at 1.5X and 1.6X, respectively, in the same time frame.
Our Final Take on VASO
Vaso’s strong share-price momentum appears to have a fundamental foundation, supported by its increasingly healthcare-focused business model, healthy operating momentum and a more streamlined portfolio. Together, its established sales platform and proprietary medical-products business provide multiple avenues for continued growth.
However, sustaining the rally will require consistent execution. Dependence on GE HealthCare and the competitive and regulated nature of the medical-device market remain key considerations and could moderate the pace of improvement if pressures intensify.
From a valuation standpoint, VASO still appears reasonably positioned despite its strong recent appreciation, as the stock continues to trade below the broader industry valuation. This suggests that successful execution of its healthcare-focused strategy could support further upside. However, the stock is now valued above its own recent historical average, indicating that investors have already begun pricing in some of the improvement in its business prospects. Consequently, additional appreciation will increasingly depend on sustained operating progress and successful conversion of its order pipeline into recognized business.
For existing shareholders, Vaso’s clearer healthcare focus, established operating platform and financial flexibility support staying invested. Prospective investors may also find VASO worth considering, although the magnitude of the recent rally warrants some caution. The momentum has scope to continue, but maintaining it will require the company to translate its strategic repositioning and growth opportunities into consistent operational and financial improvement.